Work

Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527)

Year: 2026
Type: article
Abstract: Background Prostatic urethral lift (PUL), an established minimally invasive surgical intervention for benign prostatic hyperplasia (BPH), may serve as a strategy to alleviate obstructive symptoms and to broaden eligibility for stereotactic ablative body radiotherapy (SAbR). We evaluated the safety and feasibility of combining PUL, spacer gel, fiducial markers, and SAbR for men with prostate cancer (PCa) who have underlying obstructive urinary symptoms due to BPH. Materials/methods This phase I, non-blinded, single-arm clinical trial included men with intermediate-risk PCa with symptomatic BPH with the American Urological Association Symptom Score (AUASS) ≥ 17. PUL, rectoprostatic spacer gel and fiducial markers were placed during a single procedure under general anesthesia. Subjects subsequently underwent SAbR to a dose of 4000 cGy in 5 fractions to the prostate and proximal seminal vesicles. Results Among the 15 enrolled study participants, four individuals experienced Clavien–Dindo grade 1–2 perioperative complications related to PUL implantation. In addition, eight patients experienced CTCAE v5.0 grade 1–2 genitourinary adverse events during or following SAbR. No grade ≥3 toxicities occurred. Mean AUASS significantly improved from 22.1 to 14.0 at 3 months post-SAbR ( p < 0.01). Mean EPIC urinary obstructive/irritative scores improved over time from 64.6 to 81.3 ( p = 0.02), and patients reached peak flow faster at 3 months post-SAbR ( p = 0.03). Conclusions PUL with spacer gel, followed by SAbR, appears to be a safe and feasible strategy for PCa patients with underlying BPH. While waiting for a longer-term follow-up, we observed a modest improvement in obstructive urinary symptoms at 3 months post-radiation.
Language: English
Subfield: Urology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W7233597947
FWCI:
Cites: 10
Cited by:
Related to: